BioAge FY2025 net loss rises 13% to USD 81 million as R&D expenses increase 25% to USD 74 million

Reuters03-24

BioAge FY2025 net loss rises 13% to USD 81 million as R&D expenses increase 25% to USD 74 million

BioAge published a full-year earnings press release, reporting collaboration revenue of USD 9.0 million and a net loss of USD 80.6 million.
Research and development expense rose 25.25% to USD 74.0 million, driven mainly by higher direct costs tied to the Novartis collaboration and BGE-102 and APJ program activities.
General and administrative expense increased 44.79% to USD 27.8 million, primarily due to higher personnel-related costs, legal fees, and insurance and taxes.
Cash, cash equivalents and marketable securities totaled USD 285.1 million as of Dec. 31, 2025, and management said existing resources are expected to fund operations through 2029.
Clinical updates included interim Phase 1 data for BGE-102 showing an 86% median hsCRP reduction at Day 14 with 120 mg once daily, with a Phase 2a cardiovascular risk trial planned for 1H 2026 and a Phase 1b/2a diabetic macular edema study planned for mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603240900PRIMZONEFULLFEED9677190) on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621067442?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621067442","market":"fut","top_or_hot":-1,"title":"BioAge FY2025 net loss rises 13% to USD 81 million as R&D expenses increase 25% to USD 74 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioAge FY2025 net loss rises 13% to USD 81 million as R&amp;D expenses increase 25% to USD 74 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          BioAge published a full-year earnings press release, reporting collaboration revenue of USD 9.0 million and a net loss of USD 80.6 million.\n        </li>\n<li>\n          Research and development expense rose 25.25% to USD 74.0 million, driven mainly by higher direct costs tied to the Novartis collaboration and BGE-102 and APJ program activities.\n        </li>\n<li>\n          General and administrative expense increased 44.79% to USD 27.8 million, primarily due to higher personnel-related costs, legal fees, and insurance and taxes.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities totaled USD 285.1 million as of Dec. 31, 2025, and management said existing resources are expected to fund operations through 2029.\n        </li>\n<li>\n          Clinical updates included interim Phase 1 data for BGE-102 showing an 86% median hsCRP reduction at Day 14 with 120 mg once daily, with a Phase 2a cardiovascular risk trial planned for 1H 2026 and a Phase 1b/2a diabetic macular edema study planned for mid-2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603240900PRIMZONEFULLFEED9677190) on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioAge FY2025 net loss rises 13% to USD 81 million as R&D expenses increase 25% to USD 74 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioAge FY2025 net loss rises 13% to USD 81 million as R&D expenses increase 25% to USD 74 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioAge FY2025 net loss rises 13% to USD 81 million as R&amp;D expenses increase 25% to USD 74 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          BioAge published a full-year earnings press release, reporting collaboration revenue of USD 9.0 million and a net loss of USD 80.6 million.\n        </li>\n<li>\n          Research and development expense rose 25.25% to USD 74.0 million, driven mainly by higher direct costs tied to the Novartis collaboration and BGE-102 and APJ program activities.\n        </li>\n<li>\n          General and administrative expense increased 44.79% to USD 27.8 million, primarily due to higher personnel-related costs, legal fees, and insurance and taxes.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities totaled USD 285.1 million as of Dec. 31, 2025, and management said existing resources are expected to fund operations through 2029.\n        </li>\n<li>\n          Clinical updates included interim Phase 1 data for BGE-102 showing an 86% median hsCRP reduction at Day 14 with 120 mg once daily, with a Phase 2a cardiovascular risk trial planned for 1H 2026 and a Phase 1b/2a diabetic macular edema study planned for mid-2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603240900PRIMZONEFULLFEED9677190) on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2V16.EUR","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL4sb3BL:1","article_id":"2621067442","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621067442","pubTimestamp":1774357309,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioAge published a full-year earnings press release, reporting collaboration revenue of USD 9.0 million and a net loss of USD 80.6 million.Research and development expense rose 25.25% to USD 74.0 million, driven mainly by higher direct costs tied to the Novartis collaboration and BGE-102 and APJ program activities.General and administrative expense increased 44.79% to USD 27.8 million, primarily due to higher personnel-related costs, legal fees, and insurance and taxes.Cash, cash equivalents and marketable securities totaled USD 285.1 million as of Dec. 31, 2025, and management said existing resources are expected to fund operations through 2029.Clinical updates included interim Phase 1 data for BGE-102 showing an 86% median hsCRP reduction at Day 14 with 120 mg once daily, with a Phase 2a cardiovascular risk trial planned for 1H 2026 and a Phase 1b/2a diabetic macular edema study planned for mid-2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BIOA":"BioAge Labs Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4112":"金融交易所和数据","BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC"},"translate_title":"BioAge 2025财年净亏损增加13%至8100万美元，研发费用增加25%至7400万美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BIOA":0.9},"content_text":"BioAge FY2025 net loss rises 13% to USD 81 million as R&D expenses increase 25% to USD 74 million\n    \n\n\n          BioAge published a full-year earnings press release, reporting collaboration revenue of USD 9.0 million and a net loss of USD 80.6 million.\n        \n\n          Research and development expense rose 25.25% to USD 74.0 million, driven mainly by higher direct costs tied to the Novartis collaboration and BGE-102 and APJ program activities.\n        \n\n          General and administrative expense increased 44.79% to USD 27.8 million, primarily due to higher personnel-related costs, legal fees, and insurance and taxes.\n        \n\n          Cash, cash equivalents and marketable securities totaled USD 285.1 million as of Dec. 31, 2025, and management said existing resources are expected to fund operations through 2029.\n        \n\n          Clinical updates included interim Phase 1 data for BGE-102 showing an 86% median hsCRP reduction at Day 14 with 120 mg once daily, with a Phase 2a cardiovascular risk trial planned for 1H 2026 and a Phase 1b/2a diabetic macular edema study planned for mid-2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603240900PRIMZONEFULLFEED9677190) on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621067442","isCrawlerRequest":true}